sTREM2, a poten­tial bio­marker in AD

By

sTREM2, a poten­tial bio­marker in AD

sTREM2 cor­rel­ates with microglia activ­a­tion, and higher CSF sTREM2 levels can be linked to reduced cog­nit­ive decline and slower rates of Plaque accu­mu­la­tion in AD patients.

Increased sol­uble TREM2 in cerebrospinal fluid is asso­ci­ated with reduced cog­nit­ive and clin­ical decline in Alzheimer’s disease.

Ewers M, Fran­zmeier N, Suárez-Cal­vet M, Morenas-Rodrig­uez E, Caballero MAA, Klein­ber­ger G, Pic­cio L, Cruchaga C, Dem­ing Y, Dichgans M, Tro­janowski JQ, Shaw LM, Weiner MW, Haass C; Alzheimer’s Dis­ease Neuroima­ging Ini­ti­at­ive. Sci Transl Med. 2019 Aug 28;11(507):eaav6221. doi: 10.1126/scitranslmed.aav6221. PMID: 31462511 

PDF